---
title: "HCG"
slug: "hcg"
type: "compound"
category: "Sexual Wellness"
url: "https://peptidesciencethailand.com/compounds/hcg"
description: "Human chorionic gonadotropin, an LH-mimetic used in hormone support and fertility protocols. Clinical applications, mechanism, and prescribing context."
---
# HCG

*Gonadotropin Hormone, LH-Mimetic Signaling for Reproductive and Hormonal Research*

**Category:** Sexual Wellness  
**Format:** Auto-Injector Pen  
**Amount:** 5,000 IU  
**Purity:** >99.0% (HPLC)

## Overview

Human chorionic gonadotropin (HCG) is a heterodimeric glycoprotein hormone consisting of two non-covalently linked subunits: an alpha subunit of 92 amino acids that is shared with luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH), and a unique beta subunit of 145 amino acids that confers biological specificity. The beta subunit contains extensive glycosylation with both N-linked and O-linked oligosaccharides that are critical for receptor binding, signal transduction, and the notably long circulating half-life of approximately 24-36 hours, substantially longer than LH's half-life of approximately 20 minutes.

HCG's biological activity is mediated through binding to the luteinizing hormone/choriogonadotropin receptor (LHCGR), a G protein-coupled receptor expressed on gonadal cells. In the testes, LHCGR is expressed on Leydig cells, where activation triggers a cAMP/PKA signaling cascade that stimulates the steroidogenic acute regulatory protein (StAR), which facilitates cholesterol transport into the mitochondria, the rate-limiting step in steroidogenesis. Within the mitochondria, cholesterol is converted to pregnenolone by CYP11A1 (cholesterol side-chain cleavage enzyme), and subsequently metabolized through the steroidogenic pathway to produce testosterone and other androgens.

The LH-mimetic activity of HCG has made it an essential tool in reproductive medicine and hormonal research. In male physiology, HCG administration stimulates intratesticular testosterone production, providing gonadal stimulation without suppressing the hypothalamic-pituitary axis in the way that exogenous testosterone does. This distinction is particularly relevant in the context of testosterone replacement therapy (TRT), where exogenous testosterone administration suppresses gonadotropin secretion through negative feedback, leading to reduced intratesticular testosterone, decreased spermatogenesis, and testicular atrophy. Co-administration of HCG during TRT can maintain intratesticular testosterone levels and preserve testicular function.

Beyond testosterone production, Leydig cell stimulation by HCG maintains the production of other intratesticular hormones and factors including estradiol (via aromatase), INSL3 (insulin-like factor 3, a marker of Leydig cell function), and various paracrine factors that support the seminiferous tubule microenvironment. Research has demonstrated that HCG maintains testicular volume and spermatogenic potential during exogenous androgen administration, findings that have significant implications for fertility preservation in individuals receiving hormonal therapies.

In female reproductive physiology, HCG mimics the LH surge that triggers oocyte maturation and ovulation. The binding of HCG to LHCGR on granulosa cells of the preovulatory follicle activates a cascade that includes resumption of meiosis in the oocyte, cumulus cell expansion, follicular wall degradation, and ultimately follicular rupture and oocyte release. Post-ovulation, HCG supports the transformation of the ruptured follicle into the corpus luteum, which produces progesterone essential for early pregnancy maintenance.

Recent research has identified HCG receptors (LHCGR) in extra-gonadal tissues including the uterine endometrium, myometrium, brain, adrenal cortex, and various immune cells. These findings suggest broader physiological roles for LH/HCG signaling beyond reproduction. In the brain, LHCGR activation has been associated with neuroprotective effects, and research has explored potential cognitive implications of LH/HCG signaling in aging populations where gonadotropin levels change substantially.

HCG also influences metabolic pathways relevant to body composition. Research has demonstrated interactions between HCG signaling and adipose tissue metabolism, though these effects are complex and context-dependent. The relationship between gonadal hormone production stimulated by HCG and metabolic parameters including insulin sensitivity, lipid metabolism, and body fat distribution is an area of ongoing investigation.

The recombinant and highly purified urinary forms of HCG used in research and clinical applications have well-characterized pharmacokinetic profiles. After subcutaneous injection, HCG reaches peak plasma concentrations within 6-12 hours, with a terminal half-life of 24-36 hours, enabling dosing protocols of 2-3 administrations per week for sustained gonadal stimulation.

The auto-injector pen format delivers HCG in a pre-mixed solution at 5,000 IU total capacity, enabling precise dose selection for subcutaneous administration without reconstitution or manual preparation. This format simplifies the multi-dose protocols commonly used in HCG-based treatment regimens.

## Mechanism of Action

### Step 1: LHCGR Receptor Activation

HCG binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on Leydig cells in the testes or theca/granulosa cells in the ovaries, initiating G protein-coupled receptor signaling through cAMP/PKA intracellular cascades.

### Step 2: StAR Protein Activation & Cholesterol Transport

cAMP/PKA signaling activates the steroidogenic acute regulatory protein (StAR), which facilitates the rate-limiting transport of cholesterol from the outer to the inner mitochondrial membrane, initiating the steroidogenic pathway.

### Step 3: Steroidogenesis Cascade Initiation

Within the mitochondria, CYP11A1 converts cholesterol to pregnenolone, which is subsequently metabolized through enzymatic steps involving 3-beta-HSD, CYP17A1, and 17-beta-HSD to produce testosterone and other steroid hormones.

### Step 4: Intratesticular Hormone Milieu Maintenance

HCG-stimulated Leydig cells produce testosterone, estradiol (via aromatase), INSL3, and paracrine factors that maintain the seminiferous tubule microenvironment. This preserves spermatogenesis and testicular volume independently of pituitary gonadotropin secretion.

### Step 5: Systemic Androgen & Metabolic Effects

HCG-stimulated testosterone production enters systemic circulation, supporting androgen-dependent functions including muscle protein synthesis, bone mineral maintenance, erythropoiesis, libido, and cognitive function, while maintaining gonadal axis integrity.

## Researched Benefits

### Gonadal Function Preservation

HCG maintains intratesticular testosterone production and testicular volume through direct Leydig cell stimulation via the LHCGR. This is particularly significant during exogenous androgen administration, where suppressed pituitary gonadotropins would otherwise lead to Leydig cell quiescence, reduced intratesticular testosterone, and testicular atrophy.

### Spermatogenesis Support

By maintaining intratesticular testosterone levels and the paracrine signaling environment of the seminiferous tubules, HCG supports ongoing spermatogenesis. Research demonstrates that HCG co-administration during hormonal therapies preserves sperm production potential, which is relevant for fertility preservation in individuals receiving testosterone or other hormonal treatments.

### Hormonal Balance Maintenance

HCG-stimulated steroidogenesis produces not only testosterone but also estradiol, DHEA, and other steroid intermediates that contribute to overall hormonal homeostasis. This multi-hormone production pattern more closely mimics natural gonadal function than isolated testosterone replacement alone.

### Reproductive Medicine Applications

HCG has well-established applications in reproductive medicine for both male and female contexts. Its LH-mimetic activity enables ovulation triggering, corpus luteum support, and evaluation of gonadal function. Decades of clinical use have produced extensive safety and efficacy data across these applications.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 250-500 IU administered 2-3 times per week subcutaneously, or as directed by the your specialist based on clinical indication and hormonal monitoring |
| Route | Subcutaneous injection via auto-injector pen |
| Duration | Duration determined by clinical indication. Protocols range from short-term diagnostic uses to ongoing administration concurrent with hormonal therapy. |
| Cycle Notes | Dosing protocols vary substantially based on indication. For gonadal maintenance during testosterone therapy, typical protocols use 250-500 IU 2-3 times weekly. For fertility stimulation, higher doses may be used in structured protocols. Serum testosterone, estradiol, and gonadotropin levels guide dose adjustments. |
| Reconstitution | No reconstitution required. The auto-injector pen contains pre-mixed HCG solution at 5,000 IU total capacity. Store in refrigerator at 2-8 degrees C. Protect from light. Use within the specified timeframe after first use. |

> **Specialist note:** HCG administration requires baseline hormonal evaluation including testosterone (total and free), estradiol, LH, FSH, and semen analysis if fertility is a consideration. HCG stimulates aromatase activity and can increase estradiol levels, which may require monitoring and management. Individuals with hormone-sensitive conditions require careful evaluation before HCG initiation.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Pre-filled Auto-Injector Pen |
| Amount | 5,000 IU per pen |
| Purity | >99.0% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Sequence | Heterodimeric glycoprotein: alpha subunit (92 amino acids, shared with LH/FSH/TSH) + beta subunit (145 amino acids, HCG-specific) with extensive N-linked and O-linked glycosylation |
| Molecular Weight | Approximately 36,700 g/mol (glycosylated form) |
| Storage | Store refrigerated at 2-8 degrees C. Protect from light. Do not freeze. Use within specified timeframe after first use. |
| Appearance | Clear, colorless solution in pre-filled pen |

## Medical Guidance

HCG directly stimulates gonadal steroidogenesis and can significantly alter hormonal profiles including testosterone, estradiol, and downstream metabolites. Pre-treatment evaluation must include comprehensive hormonal panel, assessment of hormone-sensitive conditions, and fertility status evaluation. HCG-stimulated aromatase activity can elevate estradiol, potentially requiring monitoring or adjunctive management. Individuals with certain hormone-sensitive conditions are not candidates for HCG administration. Ongoing hormonal monitoring throughout treatment is essential.

## Frequently Asked Questions

### What is HCG and how does it work?

HCG (human chorionic gonadotropin) is a glycoprotein hormone that mimics the action of luteinizing hormone (LH) by binding to the same receptor (LHCGR). In males, this stimulates Leydig cells in the testes to produce testosterone and other steroid hormones. In females, it triggers ovulation and supports corpus luteum function. Its long half-life (24-36 hours) compared to LH (20 minutes) enables practical dosing protocols.

### Why is HCG used alongside testosterone therapy?

Exogenous testosterone suppresses pituitary LH and FSH secretion through negative feedback, which leads to decreased intratesticular testosterone production, reduced spermatogenesis, and testicular atrophy. HCG provides direct Leydig cell stimulation independent of pituitary function, maintaining intratesticular testosterone levels, testicular volume, and spermatogenic potential during exogenous androgen administration.

### Does HCG require medical supervision?

Yes. HCG directly modulates gonadal steroidogenesis and significantly affects hormonal profiles. Medical supervision is essential for baseline hormonal evaluation, dose determination, monitoring of testosterone and estradiol levels during treatment, and assessment of any hormone-sensitive conditions. The dosing protocol must be individualized based on clinical indication and ongoing laboratory monitoring.

### Can HCG increase estrogen levels?

Yes. HCG stimulates Leydig cell testosterone production, and a portion of this testosterone is converted to estradiol by the aromatase enzyme. HCG also directly upregulates aromatase activity. Rising estradiol levels are a normal physiological response to HCG administration but require monitoring. A specialist may recommend estradiol monitoring and potentially adjunctive management if levels rise beyond target ranges.

### What is the advantage of the pen format for HCG?

Traditional HCG requires reconstitution of lyophilized powder with bacteriostatic water, manual measurement of IU doses using syringes, and refrigerated storage of the reconstituted solution. The auto-injector pen contains pre-mixed HCG solution with a dose-selection mechanism, eliminating reconstitution, simplifying dose accuracy, and enabling convenient self-administration under specialist guidance.

## Related Compounds

- /compounds/pt-141
- /compounds/kisspeptin
- /compounds/melanotan-2